Boxer Capital’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Boxer Capital’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,897,500	Closed	-$204M	–	83
2023 Q1	$204M	Hold	1,897,500	–	–	10%	1
2022 Q4	$209M	Buy	1,897,500 +183,500	+11%	+$11.9M	11%	1
2022 Q3	$101M	Hold	1,714,000	–	–	5.69%	3
2022 Q2	$48.4M	Hold	1,714,000	–	–	3.06%	8
2022 Q1	$64.7M	Buy	+1,714,000	New	+$67.8M	3.33%	11

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Boxer Capital's RXDX Position: Q2 2023 in Review

Boxer Capital sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,897,500 shares — an estimated $204M sold.

Boxer Capital first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $209M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Boxer Capital reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Boxer Capital sold 1,897,500 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $204M.
Boxer Capital first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Boxer Capital's Prometheus Biosciences, Inc. Common Stock position peaked at $209M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Boxer Capital's 13F filing for Q2 2023, filed 14 Aug 2023.